Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : NNG-DEPO
Product Type : Protein
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Desidustat in the Treatment of Anemia in CKD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 09, 2019
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 15, 2019
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 14, 2018
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 13, 2018
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 09, 2018
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 23, 2015
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 23, 2015
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable